• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    A

    Arlington Dermatology

    EST. 1968
    38论文总数
    992引用总数

    论文量&引用量时间轴

    机构学者

    论文(38)

    年份
    起
    –
    止
    排序
    1Efficacy and Safety of Risankizumab in Paediatric Patients with Psoriasis in the OptIMMize-1 Phase III Study
    Nina Magnolo,Wine Lee Lara,Adam Reich,Irene Lara-Corrales,Akimichi Morita,Michael Bukhalo,Asunción Vicente,Toni Anschutz, Rosie D Lyles,Tshepiso Madihlaba,Kristina Unnebrink,Doug Ashley,

    Abstract Background Treatment options for paediatric patients with psoriasis are limited, and additional, more advanced therapies are needed. Risankizumab is an interleukin-23 inhibitor approved to treat moderate-to-severe psoriasis in adults. Objectives To evaluate efficacy and safety of risankizumab through 52 weeks in paediatric patients with moderate-to-severe psoriasis. Methods OptIMMize-1 (NCT04435600) was a phase III, multicentre, 4-part study. Parts 1, 3, and 4 were 52-week, open-label studies. Part 2 consisted of a 16-week initial treatment period (Period A; 2:1 risankizumab:ustekinumab randomization), followed by an up to 36-week randomized treatment or withdrawal period (Period B) for risankizumab responders, with a potential 16-week retreatment period (Period C) for patients who experience a disease flare. Risankizumab nonresponders and patients randomized to ustekinumab in Period A received risankizumab during Period B. Key outcomes included the proportion of patients achieving a static Physician’s Global Assessment (sPGA) score of clear/almost clear (sPGA0/1), sPGA0/1 with ≥2-grade improvement (sPGA0/1+≥2GI), or ≥75%/≥90%/100% improvement in PASI (PASI75/90/100). The study also assessed itch severity, quality of life, and safety. Results A total of 137 patients enrolled. In Part 2 (risankizumab, n = 54; ustekinumab, n = 28), week 16 response rates were similar: sPGA0/1 was 79.6% for risankizumab and 75.0% for ustekinumab; sPGA0/1+≥2 GI rates were 68.5% vs. 67.9%; PASI75 rates were 85.2% vs. 85.7%; and PASI90 rates were 64.8% vs. 60.7%. PASI100 responses were higher with risankizumab (40.7%) than with ustekinumab (17.9%). In Part 4 (n = 30), week 16 rates were sPGA0/1: 90.0%, sPGA0/1+≥2GI: 83.3%, PASI75: 86.7%, PASI90: 76.7%, and PASI100: 43.3%; week 52 responses were maintained or improved. Skin clearance outcomes in Parts 1 and 3 were consistent with those observed with continuous risankizumab treatment in Parts 2 and 4. Improvements in itch and quality of life (assessed in Part 2 only) were observed at weeks 16 and 52. Risankizumab safety profiles were consistent with those observed in prior adult psoriasis studies. Conclusions Risankizumab was well tolerated in paediatric patients, resulting in marked improvements in skin clearance, itching, and quality of life after 16 weeks of treatment. Efficacy was maintained or improved at week 52, supporting risankizumab use for moderate-to-severe psoriasis in this population.

    2026British Journal of Dermatology(2026)
    引用
    AI阅读
    加入学术空间
    2Efficacy and Safety of Risankizumab in Pediatric Patients with Psoriasis: Results from the OptIMMize-1 Phase 3 Study
    Nina Magnolo,Lara Wine Lee,Adam Reich, Irene Lara-Corrales,Akimichi Morita,Michael Bukhalo,Asuncion Vicente, Toni Anschutz, Rosie D. Lyles,Kristina Unnebrink, Cynthia Huber, Doug G. Ashley,

    Pediatric psoriasis (PsO) treatment options are limited. Risankizumab (RZB) is an interleukin 23 inhibitor approved for moderate-to-severe PsO in adults. OptIMMize-1 (NCT04435600) was a phase 3, multicenter, 4-part study of RZB in pediatric patients with moderate-to-severe PsO. In part 2 period A (P2PA), adolescents (12 to <18 years) were randomized 2:1 to RZB or ustekinumab (UST) for 16 weeks (W). In Part 4 (P4), children (6 to <12 years) received open-label RZB for 52W. Co-primary endpoints (≥75% improvement in Psoriasis Area and Severity Index [PASI75], static Physician’s Global Assessment of clear/ almost clear [sPGA0/1], sPGA0/1 with ≥2-grade improvement [sPGA0/1+≥2GI]), secondary endpoints (PASI90/100), and safety were assessed (descriptive statistics). In P2PA (RZB, n=54; UST, n=28), W16 primary endpoint response rates (95%CI) were similar with RZB vs UST (PASI75: 85.2% [72.9,93.4] vs 85.7% [67.3,96.0]; sPGA0/1: 79.6% [66.5,89.4] vs 75.0% [55.1,89.3]; sPGA0/1+≥2GI: 68.5% [54.4,80.5] vs 67.9% [47.6,84.1]). RZB vs UST rates were PASI90: 64.8% (50.6,77.3) vs 60.7% (40.6,78.5) and PASI100: 40.7% (27.6,55.0) vs 17.9% (6.1,36.9). In P4 (n=30), W16 rates (95%CI) were PASI75: 86.7% (69.3,96.2); sPGA0/ 1: 90.0% (73.5,97.9); sPGA0/1+≥2GI: 83.3% (65.3,94.4); PASI90: 76.7% (57.7,90.1); and PASI100: 43.3% (25.5,62.6). W52 responses were maintained or improved. The RZB safety profile was generally consistent with adult studies in PsO. These findings support RZB to treat pediatric PsO.

    2026JOURNAL OF INVESTIGATIVE DERMATOLOGY(2026)
    引用
    AI阅读
    加入学术空间
    3Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aimm) Study
    Richard B. Warren,Lev Pavlovsky,Antonio Costanzo,Michael Bukhalo,Neil J. Korman,Yu-Huei Huang,Georgios Kokolakis,Andreas Pinter,Nadia Ibrahim, Yanbing Zheng,Leonidas Drogaris,Vassilis Stakias,

    IntroductionRisankizumab has demonstrated superior efficacy compared to other psoriasis treatments, including secukinumab, adalimumab, and ustekinumab; switching to risankizumab from other psoriasis treatments has shown superior clinical and quality of life (QoL) outcomes. We evaluated the efficacy and safety of directly switching patients with moderate-to-severe plaque psoriasis and a suboptimal response to interleukin (IL)-17 inhibitors (secukinumab or ixekizumab) to risankizumab. MethodsThis 52-week, phase 3b study enrolled patients (>= 18 years) with moderate-to-severe plaque psoriasis who had previously been treated with the recommended dose of secukinumab or ixekizumab for >= 6 months but did not achieve an optimal response (static Physician's Global Assessment [sPGA] 2/3; body surface are [BSA] 3- < 10%). Patients received subcutaneous risankizumab (150 mg) without washout. The primary endpoint was the proportion of patients achieving sPGA of 0/1 at week 16. Secondary endpoints included sPGA 0/1 at week 52, sPGA 0, Dermatology Life Quality Index (DLQI) 0/1, and Psoriasis Symptoms Scale (PSS) 0 at weeks 16 and 52. Safety was monitored throughout the study. ResultsThe study included 244 patients. sPGA 0/1 was achieved by 57.4% and 62.3% at week 16 and 52. At week 16, sPGA 0, DLQI 0/1, and PSS 0 were achieved by 20.5%, 40.2%, and 20.9%, respectively. At week 52, these proportions increased to 27.1% for sPGA 0, 47.2% for DLQI 0/1, and 27.5% for PSS 0. Most frequently reported adverse events (reported in >= 5% of patients) in risankizumab-treated patients were COVID-19 infection (8.6%) and nasopharyngitis (5.7%). No new safety signals were observed. ConclusionsDirectly switching to risankizumab improved outcomes and QoL in patients with moderate-to-severe psoriasis who had suboptimal responses to anti-IL-17 inhibitors (secukinumab or ixekizumab). The safety results are consistent with previously reported safety of risankizumab. This study supports the efficacy of risankizumab in patients previously treated with biologics, including IL-17 inhibitors, and suggests a direct switch to risankizumab for improved clinical outcomes and QoL. Clinical TrialsClinicalTrials.gov identifier: NCT04102007.

    2025Dermatology and Therapy(2025)引用:1
    引用
    AI阅读
    加入学术空间
    4Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body
    Melinda J. Gooderham,Javier Alonso-Llamazares,Jerry Bagel,Neal Bhatia,Michael Bukhalo,Janet DuBois,Laura K. Ferris,Lawrence Green,Leon H. Kircik,Benjamin Lockshin, Wei Jing Loo,Kim A. Papp,

    Current topical treatments for scalp psoriasis are limited by formulation, efficacy, and/or safety. To assess safety and efficacy of roflumilast foam, 0.3%, in patients with psoriasis of the scalp and body. This was a phase 3 double-blinded, vehicle-controlled randomized clinical trial conducted between August 24, 2021, and June 3, 2022, at 49 sites in Canada and the US. Eligible participants were 12 years and older with plaque psoriasis affecting up to 25% of the scalp and body, at least 10% of the scalp, and up to 20% of nonscalp areas, with a minimum Scalp−Investigator Global Assessment (S-IGA) score of 3 (moderate), and minimum Body−IGA (B-IGA) score of 2 (mild). Data analyses were performed from September 9 to December 30, 2022. Once-daily roflumilast foam, 0.3%, or vehicle for 8 weeks. Coprimary end points were S-IGA and B-IGA success (clear [0] or almost clear [1] plus ≥2-grade improvement) at week 8. Secondary end points included S-IGA success at weeks 2 and 4, change in Scalp Itch−Numeric Rating Scale (SI-NRS), and SI-NRS and Worst Itch−NRS (WI-NRS) success (≥4-point improvement in patients with baseline score of ≥4). Safety and tolerability were also assessed. A total of 432 patients (mean [SD] age, 47.3 [14.8] years; 243 women [56.3%]) were randomized to roflumilast foam (n = 281) or vehicle (n = 151). At week 8, 66.4% of the roflumilast group achieved S-IGA success vs 27.8% of the vehicle group (P < .001); and 45.5% of the roflumilast group achieved B-IGA success compared with 20.1% of the vehicle group (P < .001). Rates for S-IGA success at week 2 and SI-NRS and WI-NRS success at weeks 2, 4, and 8 were significantly higher for roflumilast vs vehicle. Improvements in SI-NRS were greater for the roflumilast vs the vehicle group as early as the first assessment (24 hours after the first application). Both study groups had low rates of adverse events and favorable tolerability profiles. This randomized clinical trial found that roflumilast foam, 0.3%, improved signs and symptoms of psoriasis on the scalp and body, including pruritus, with low rates of adverse events in patients 12 years and older. These results demonstrate the potential of roflumilast foam, 0.3%, as monotherapy for patients with psoriasis of the scalp and body. ClinicalTrials.gov Identifier: NCT05028582

    2025JAMA Dermatology(2025)
    引用
    AI阅读
    加入学术空间
    5Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes.
    Bruce E. Strober,Michael Bukhalo,April W. Armstrong,David Pariser,Leon Kircik, Brian Johnson, Paul Montgomery,Tobin J. Dickerson

    Objective: This study (MATCH) was designed to assess the clinical utility of a machine-learning based tool (Mind.Px) that predicts patient response to the most common biologic drug classes used in the management of psoriasis patients. Methods: The MATCH study was designed to assess Mind.Px utility in physician decision making and patient outcomes. Psoriasis patients who were biologic naïve or those who were approaching a change due to non-response were enrolled into the study (N=112). At baseline, a dermal biomarker patch was applied to lesional skin and Mind.Px test results were provided to physicians prior to biologic selection. The choice of biologic for each patient was recorded and in the case of physician non-concordance with Mind.Px test results, a questionnaire completed to determine the reason for non-concordance. Patients were evaluated at weeks 4, 8, 12, and 16 after baseline using PASI, PGA, and BSA. Statistical analysis between groups was performed using Fisher’s exact test. Results: Physician prescribing behavior was measured with and without the inclusion of Mind.Px test results in the decision-making process. This data set was compared to a previously obtained data set in which dermal biomarker patches were applied at baseline, but Mind.Px results were not provided to physicians at any point during treatment (N=180). Statistical analysis of concordance between the Mind.Px-informed and Mind.Px-uninformed groups within the MATCH study (84.4% vs 53.8%, respectively) showed that when given access to Mind.Px results, physician behavior was significantly altered (p = 0.0022). Furthermore, analysis of those patients who have completed the study showed improved clinical outcomes in those patients whose physicians were provided Mind.Px test results. Specifically, this cohort reached PASI75 sooner than those who were not provided test results (p = 0.004). Conclusion: These results provide an interim measurement of the clinical utility of Mind.Px by demonstrating that physicians will utilize this test in psoriasis biologic decision making and by doing so, this leads to improved patient outcomes. These improved patient outcomes can also potentially translate into tremendous cost savings for healthcare systems. Mind.Px can effectively minimize the trial-and-error approach to psoriasis treatment, and provide physicians, patients, and payers with a powerful tool for improving psoriasis patient management.

    2025Dermatology and Therapy(2025)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 38 篇论文

    合作机构(62)

    勃林格殷格翰制药合作论文 7
    艾伯维合作论文 6
    德克萨斯大学休斯顿健康科学中心合作论文 5
    Queen''s University合作论文 4
    犹他大学合作论文 4
    礼来公司合作论文 4
    柏林夏里特大学医学院合作论文 4
    东弗吉尼亚医学院合作论文 4
    加利福尼亚州立大学洛杉矶分校合作论文 4
    亨利·福特医疗系统合作论文 3

    机构统计